The eight factors that will determine the impact of GLP-1s
Sizing the full, eventual impact of GLP-1s is difficult—here are the eight factors that will determine the size of their impact.
At a glance
Read on to get our full commentary, or use the links below to jump to a specific area of interest:
-
The eight factors that will determine the impact of GLP-1s
- Influencing factor #1: The efficacy of GLP-1s
- Influencing factor #2: The tolerability/safety of GLP-1s
- Influencing factor #3: The clinical scope of GLP-1s
- Influencing factor #4: The longevity of GLP-1s
- Influencing factor #5: The price of GLP-1s
- Influencing factor #6: Risk contracting prevalence for GLP-1s
- Influencing factor #7: Insurance coverage of GLP-1s
- Influencing factor #8: Equitable access to GLP-1s
- Influencing factor #1: The efficacy of GLP-1s
In last week’s blog post, we delved into the what and why behind the current surge in interest and demand for GLP-1s. And it’s clear that these medications have significant potential to not only meaningfully improve patient outcomes, but also to reshape the business models underlying chronic care today. But sizing the full, eventual impact of these drugs remains difficult, given a large number of unknowns/lingering unanswered questions, and the fast pace of change when it comes to continued clinical innovation, as well as the shifting reimbursement and coverage landscape.
So in today’s blog, we’ll share the short-list of factors that we think will ultimately shape the magnitude of the impact of GLP-1s. For each factor, we’ll share: 1) Why it matters, 2) the current state, and 3) the future outlook.
Union Healthcare Insight
Log in to continue reading
Not a member yet? Create a free account for limited access.
Related insights
Can AI help close a persistent gap in cardiovascular care?
What’s next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care
Specialty value-based care: The next phase of VBC